Literature DB >> 17382800

Immunotherapeutic strategies for high-risk bladder cancer.

Padmanee Sharma1, Lloyd J Old, James P Allison.   

Abstract

Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-grade superficial disease. The nonspecific immune modulation that occurs as a result of BCG therapy is not well understood; however, the success of BCG therapy provides a basis for the exploration of mechanisms related to immune responses and the development of novel immunotherapeutic agents for the treatment of high-risk disease. In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17382800      PMCID： PMC6009830          DOI： 10.1053/j.seminoncol.2006.12.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  76 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Authors:  A M Thornton; E M Shevach
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

Review 3.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

4.  Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells.

Authors:  B Doe; M Selby; S Barnett; J Baenziger; C M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

5.  Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope.

Authors:  M H Ryan; J A Bristol; E McDuffie; S I Abrams
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

6.  Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma.

Authors:  Padmanee Sharma; Yu Shen; Sijin Wen; Dean F Bajorin; Victor E Reuter; Lloyd J Old; Achim A Jungbluth
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

7.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

8.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

9.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245
View more
  9 in total

Review 1.  Is complement good or bad for cancer patients? A new perspective on an old dilemma.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Trends Immunol       Date:  2009-05-08       Impact factor: 16.687

Review 2.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

Review 3.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

Review 4.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 5.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

6.  An anti-ubiquitin antibody response in transitional cell carcinoma of the urinary bladder.

Authors:  Peter U Ardelt; Jan Ebbing; Fabian Adams; Cora Reiss; Wadih Arap; Renata Pasqualini; Alexander Bachmann; Ulrich Wetterauer; Hubertus Riedmiller; Burkhard Kneitz
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

Review 7.  BCG in Bladder Cancer Immunotherapy.

Authors:  Song Jiang; Gil Redelman-Sidi
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

8.  Granuloma cells in chronic inflammation express CD205 (DEC205) antigen and harbor proliferating T lymphocytes: similarity to antigen-presenting cells.

Authors:  Haruo Ohtani
Journal:  Pathol Int       Date:  2013-02-22       Impact factor: 2.534

Review 9.  Complement inhibition in cancer therapy.

Authors:  Ruben Pio; Daniel Ajona; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-24       Impact factor: 10.671
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.